Pfizer’s cancer drug Bosulif was found superior to Novartis’ Gleevec in a late-stage study on untreated patients with a form of blood and bone marrow cancer.
https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png00Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2016-12-05 10:19:532016-12-05 13:35:21Pfizer blood cancer drug tops standard therapy
